The board of directors of JW (Cayman) Therapeutics Co. Ltd. announced that, Dr. Sungwon Song has been appointed as a non-executive Director with effect from August 29, 2023. Dr. Song, aged 42, has been working at Mirae Asset Global Investments (Hong Kong) Limited as a healthcare private equity investor since July 2018, advising on securities and asset management mainly on the portfolio of healthcare sector. He has over 8 years of private healthcare investment experience. Prior to his employment with Mirae Asset Global Investments (Hong Kong) Limited, he was a healthcare venture capitalist at Mirae Asset Capital Co. Ltd. in Seoul, South Korea, from July 2016 to July 2018. Prior to that, he was a healthcare investment analyst at Mirae Asset Global Investment LLC in New York, the United States, from July 2015 to June 2016. Dr. Song obtained a bachelor of science degree in biotechnology and genetic engineering from Korea University in South Korea in August 2005 and a master of arts degree in biotechnology of biological sciences from Columbia University in the United States in August 2008. Dr. Song further obtained a Ph.D. in molecular cellular developmental biology from the Ohio State University in the United States in December 2014. The board is also announced that, with effect from August 29, 2023, Dr. Krishnan Viswanadhan and Dr. Ann Li Lee have been re-designated as independent non-executive Directors. Previously, Dr. Viswanadhan and Dr. Lee were non-executive Directors. Dr. Viswanadhan, aged 45, has served as a member of the Board since November 2019. Dr. Viswanadhan has been the President and Chief Operating Officer at Be Biopharma since July 2021 and an independent board member of Cargo Therapeutics. He was a senior vice president and global cell therapy franchise lead at BMS from August 2019 to July 2021. Prior to that, he served at Celgene Corporation ("Celgene") starting as an executive director, global project leader and strategic development leader in 2014 and then as Vice President of Business Development and Global Alliances. Prior to that, he served at F. Hoffmann-La Roche Ltd. ("Roche") where he first began as program manager in the drug regulatory department in July 2002. Dr. Viswanadhan obtained a bachelor of science degree and a doctor of pharmacy degree from Rutgers University in the United States in May 2001. He obtained a master of business administration degree from Cornell University in the United States in May 2010. Dr. Lee, aged 62, has served as a member of the Board since May 2020. Dr. Lee possesses over 30 years of experience in the biopharmaceutical industry working on vaccines, small molecules, cell therapies and gene editing. She has worked at Prime Medicine as Chief Technical Officer since October 2021. She was employed by BMS from November 2019 until July 2021 as senior vice president and head of cell therapy development and operations, and she served at Celgene from April 2018 as executive vice president and head of cell therapy development and operations. Prior to that, she joined Juno Therapeutics Inc. as executive vice president of technical operations in November 2017. Earlier in her career, she served as vice president and senior vice president in Genentech Inc. and as global head of technical development at Roche. She also worked at Merck & Co. Inc. ("Merck") beginning in 1989 where she worked in vaccines R&D at levels of increasing responsibility, and was vice president of chemical technology and engineering in the Merck manufacturing division. Dr. Lee obtained a Ph.D. in engineering and applied science from Yale University in the United States in May 1990. She obtained her bachelor of science degree from Cornell University in the United States in May 1983. She is an elected member of the National Academy of Engineering, fellow of the American Academy of Arts and Sciences and fellow of the American Institute for Medical and Biological Engineering. The board announced that, with effect from August 29, 2023, Mr. Jinyin Wang (Mr. Wang) has resigned as a non-executive Director due to his personal work arrangements and business commitment. The Board announced that the Board has established a business development and strategy committee (the Business Development and Strategy Committee) for the purposes of, among others, reviewing and making recommendations on the development strategies of the company to the board with effect from August 29, 2023. Dr. Krishnan Viswanadhan and Dr. Debra Yu, independent non-executive Directors, have been appointed as the co-chairpersons of the Business Development and Strategy committee, and Dr. Yiping James Li, an executive Director, has been appointed as a
member of the Business Development and Strategy Committee, with effect from August 29, 2023. Change Of Composition Of Board Committees: (1) Mr. Yiu Leung Andy Cheung ceased to be the chairman of the Remuneration Committee; (2) Mr. Kin Cheong Kelvin Ho (Mr. Ho) ceased to be a member of the Nomination Committee; (3) Dr. Lee, an independent non-executive Director, has been appointed as the chairman of the Remuneration Committee; (4) Dr. Song, a non-executive Director, has been appointed as a member of the Remuneration Committee; and (5) Mr. Ho, an independent non-executive Director, has been appointed as a member of the Remuneration Committee.